Reframing the Discussion on Finasteride and Neuropsychiatric Safety

The article critiques Brezis's assertion that finasteride is causally linked to depression and suicidality, emphasizing that current evidence does not establish causation. It highlights the limitations of disproportionality analyses and spontaneous reporting systems, which are prone to biases and should not be used to make population-level conclusions. The authors argue that depression and suicidality in individuals with alopecia may be influenced by pre-existing psychosocial burdens rather than finasteride itself. Large cohort studies show no increase in suicide risk with 5-alpha reductase inhibitors, though there may be transient increases in self-harm and depression. The article calls for nuanced patient monitoring and warns against fear-based messaging, which could deter patients from effective treatments and exacerbate alopecia-related distress. It advocates for rigorous research that considers dose, indication, and patient demographics to ensure balanced interpretation of finasteride's safety profile.